poisar

Stocks · News reference

Stratasys Launches Its F870 FDM System Large-Format Additive Manufacturing Platform At Toyota And Rivian Factories In The U.S.

Benzinga Newsdesk

Extending the Stratasys production-grade FDM portfolio, the F870 combines unrivaled large-format capabilities in a heated chamber backed by a suite of the strongest, most durable materials, all with a lower total cost

More stocks newsConnected markets

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

RIVNSSYSTM
Source
benzinga
Observed
Checked
Cadence
Captured once, then retained as an archive reference
Status
fresh

Keep reading

  1. Daniel Miller

    The EV Brain Drain: Lucid Is Bleeding Talent While Rivian Is Evolving

    Rivian's CFO Claire McDonough is departing for GE Vernova after nearly six years, but the transition is orderly and reflects the company's evolution from startup fundraising to mass manufacturing. In contrast, Lucid is experiencing a severe executive exodus under new CEO Silvio Napoli, including the departure of founder Peter Rawlinson, CFO Taoufiq Boussaid, and multiple senior engineers. Lucid's sweeping restructuring, layoffs, and delayed product launches signal deeper troubles, making Rivian appear the more stable long-term EV investment.

    RIVNLCIDGEVVWAGY
  3. Robert Izquierdo

    BYD vs. Rivian: Evaluating the Better Automotive Stock to Buy for 2026

    The article compares BYD, a profitable global EV giant with presence in 120 countries, against Rivian, a high-growth American EV startup backed by Amazon. While BYD trades at a valuation discount and maintains financial stability, it faces Chinese government unpredictability and domestic pricing pressures. Rivian shows improving sales momentum and narrowing losses despite U.S. EV market headwinds. The author recommends Rivian for 2026 due to its sales growth trajectory and reduced reliance on unpredictable government policies, despite its continued cash burn and funding dependency.

    RIVNAMZNBYDDYVWAGY
  4. Na

    Correction: Bioprinting Market to Reach $5.1 Billion by 2030, Driven by Regenerative Medicine Demand and AI Integration

    The global bioprinting market is projected to grow from $2.1 billion in 2024 to $5.1 billion by 2030 at a 16.1% CAGR, driven by regenerative medicine demand, pharmaceutical adoption for drug discovery, reduced animal testing, and AI integration. North America leads with 38% market share, while emerging technologies like 4D bioprinting and organ-on-chip devices expand market boundaries.

    DDDMKKGYSSYSBCCOY
  6. Benzinga Insights

    Full Transcript: Stratasys Q2 2026 Earnings Call

    On Thursday, Stratasys (NASDAQ:SSYS) discussed second-quarter financial results during its earnings call. The full transcript is provided below. This transcript is brought to you by Benzinga APIs. For real-time access

    SSYS